Private biotech company focused on developing modulators of intracellular protein-protein interactions employing a proprietary technology platform. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently in preclinical development.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2013
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in